Abstract 1308P
Background
High false positive rates in LDCT screening are an important concern. The study aims to explore the diagnostic performance of different diameter thresholds for various lung nodules to reduce unnecessary follow-up LDCT scans and the waste of medical resources.
Methods
Participants were recruited from the "Guangzhou Lung-Care Project" at the First Affiliated Hospital of Guangzhou Medical University in China between 2017 and 2021. The average transverse diameter of lung nodules was measured by semi-automatic segmentation. Positive outcomes were divided into two groups: outcome 1-lung cancer diagnosis with AAH/AIS, and outcome 2-lung cancer diagnosis without AAH/AIS. We calculated the area under the receiver-operating characteristic curves (AUCs), sensitivity, specificity, positive prediction rate(ppv) and negative prediction rate (NPV) to evaluate the diagnostic performance of lung cancer under each threshold between 5mm to 10mm.
Results
In the first year after LDCT screening, 126 cases of lung cancer (including 13 cases of AAH/AIS) were diagnosed among the participants of 11,705 (5,425 men and 6,280 women; median age 59). Increase the average transverse diameter threshold from 5 to 7mm in all lung nodules (solid, part-solid, non-solid), and gradually increase the AUC in outcome 1 (0.766 to 0.825) and outcome 2 (0.78 to 0.839). From 7 to 10mm, the AUC in outcome 1 (0.825 to 0.764) and outcome 2 (0.839 to 0.778) is gradually reduced. In the outcome 2, when the diameter threshold was increased from 5mm to 8mm, the specificity (60.06% to 90.82%) and ppv (6.57% to 19.02%) increased significantly, the sensitivity was reduced (94.02% to 76.07%). When the diameter threshold was increased from 8mm to 10mm, the sensitivity was significantly reduced (76.07% to 60.68%) and specificity (90.82% to 94.88%) and ppv (19.02% to 25.13%) increased slightly. There is no obvious difference between outcome 1 and outcome 2 in the above indicators.
Conclusions
Our study demonstrates that setting a diameter threshold of 8mm for LDCT screening of lung nodules achieves better overall diagnostic performance, reducing false positives and unnecessary follow-up scans while minimizing medical resource waste.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Wenhua Liang.
Funding
The First Affiliated Hospital of Guangzhou Medical University; China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1287P - Comparing the cost-effectiveness of perioperative immunotherapy strategies in non-small cell lung cancer
Presenter: Bharathi Muthusamy
Session: Poster session 04
1288P - Neoadjuvant therapy with anti-PD-1/PD-L1 plus platinum-base chemotherapy for resectable stage II-III non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials
Presenter: Maria Dacoregio
Session: Poster session 04
1289TiP - LANTERN study: A multi-omics digital human avatar for integrating precision medicine into clinical practice for lung cancer patients
Presenter: Emilio Bria
Session: Poster session 04
1294P - A final analysis of a phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non–small-cell lung cancer: TORG1937 (DATE study)
Presenter: Tetsuro Kondo
Session: Poster session 04
1296P - Neoadjuvant camrelizumab and apatinib in patients with resectable non-small-cell lung cancer: One-year update from a phase II trial
Presenter: Wei Guo
Session: Poster session 04
1297P - An open-label, prospective phase II study of tislelizumab in combination with chidamide as consolidation therapy in locally advanced, unresectable, stage III NSCLC
Presenter: Yi Hu
Session: Poster session 04
1298P - Chemotherapy with concurrent proton vs. photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and immune therapy
Presenter: Francesco Cortiula
Session: Poster session 04
1299P - The role of radiotherapy in extensive-stage small cell lung cancer after durvalumab-based immunochemotherapy: A retrospective study
Presenter: Lingjuan Chen
Session: Poster session 04